Institut für Tropenmedizin, Eberhard Karls Universität, Tübingen, Germany.
Euro Surveill. 2013 Jul 25;18(30):20542. doi: 10.2807/1560-7917.es2013.18.30.20542.
A number of published case reports suggest an association of tumor necrosis factor (TNF) alpha antagonist use and manifest leishmaniasis. Despite increasing popularity of antagonising TNF alpha for the treatment of autoimmune disorders, systematic research on the risk of opportunistic leishmaniasis in patients receiving these drugs is lacking. This perspective identifies areas of uncertainty regarding the safety profile of TNF alpha antagonist drugs and their clinical use in patients at risk of leishmaniasis. Then, we reflect on how current pharmacovigilance activities in Europe could be enhanced to help reduce these uncertainties. Our aim is to stimulate a debate about this important drug safety issue with potential consequences for patients receiving TNF alpha antagonists living in or travelling to areas endemic for leishmaniasis.
已有大量文献报道提示肿瘤坏死因子（TNF）α拮抗剂的使用与利什曼病的发生相关。尽管 TNFα拮抗剂在治疗自身免疫性疾病方面的应用越来越广泛，但对于接受此类药物治疗的患者发生机会性利什曼病的风险，仍缺乏系统的研究。本综述针对 TNFα拮抗剂药物的安全性特征及其在利什曼病高危患者中的临床应用，提出了一些尚待明确的问题。在此基础上，我们探讨了如何加强欧洲目前的药物警戒活动，以帮助减少这些不确定性。我们希望就这一重要的药物安全问题展开讨论，因为这可能会对居住在或前往利什曼病流行地区的接受 TNFα拮抗剂治疗的患者产生影响。
